Tengion Company Description
Tengion, Inc. operates as a regenerative medicine company.
The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.
Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery.
The company has a license agreement with Children’s Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology.
Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina. On December 29, 2014, Tengion, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
Contact Details
Address: 3929 Westpoint Boulevard Winston-Salem, Delaware 27103 United States | |
| Phone | 336-722-5855 |
Stock Details
| Ticker Symbol | TNGNQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US88034G2084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David I. Scheer | Co-Founder and Chairman of the Board |